OncoSec Medical Inc (ONCSQ)

[cameron12x]

I believe some investors wrongly perceive ONCS as a monotherapy company. As such, the results PR'ed today might be perceived as underwhelming by some.

Perception may be reality, but it's not always accurate.

The P2B combination trial with Keytruda will become the watershed event which will either make or break the company, IMHO. Combination therapies will be the dominant paradigm for treating cancer going forward.

We will see a significant run-up going into the release of interim P2B data later in Q2 or Q3 next year. It will become a binary event.